Dopamine Signaling

Overview

Dopamine is a catecholamine neurotransmitter synthesized from tyrosine by a small population of midbrain and hypothalamic neurons whose projections fan out across the forebrain. Despite representing fewer than one percent of all CNS neurons, the dopamine system carries an outsized share of the brain's work. It signals the difference between expected and received reward, gates voluntary movement, filters sensory relevance, and modulates prefrontal working memory. Failures of dopamine signaling underlie Parkinson's disease, schizophrenia, addiction, and ADHD.

Unlike fast amino-acid transmitters such as glutamate or GABA, dopamine acts slowly and broadly. Its receptors are all G-protein coupled, meaning its effects unfold over hundreds of milliseconds to seconds and extend far beyond the immediate synapse — a mode often called volume transmission. Peptides such as Semax, Selank, Bromantane, and P21 are studied for their effects on dopamine release, receptor expression, or tyrosine hydroxylase availability.

How It Works

Synthesis. In dopaminergic neurons, the rate-limiting enzyme tyrosine hydroxylase converts tyrosine to L-DOPA using tetrahydrobiopterin, iron, and oxygen. DOPA decarboxylase then strips the carboxyl group to yield dopamine. The finished transmitter is packaged into synaptic vesicles by VMAT2 against a steep proton gradient.

Release. Action potentials open voltage-gated calcium channels at the terminal; calcium entry triggers vesicle fusion with the active zone membrane — the general mechanism covered in neurotransmission. Dopamine also exhibits distinctive tonic firing patterns (slow, steady baseline) punctuated by phasic bursts (brief, high-frequency volleys that encode reward prediction errors).

Receptor families. Five receptor subtypes fall into two pharmacological classes. The D1-like family (D1, D5) couples to Gs and raises cAMP through adenylate cyclase. The D2-like family (D2, D3, D4) couples to Gi/Go and lowers cAMP while opening GIRK potassium channels. D2 autoreceptors on dopamine terminals provide negative feedback on release.

Termination. The dopamine transporter (DAT) reuptakes released dopamine into the presynaptic neuron, where monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) degrade it. DAT is the molecular target of cocaine and amphetamine.

Four Major Pathways

Nigrostriatal. Projects from the substantia nigra pars compacta to the dorsal striatum. Drives initiation and scaling of voluntary movement. Its degeneration produces Parkinson's disease.

Mesolimbic. Projects from the ventral tegmental area (VTA) to the nucleus accumbens and amygdala. Encodes reward prediction error, drives motivated behavior, and is the substrate of most drug addiction. This pathway is covered in more detail under reward circuitry.

Mesocortical. Projects from the VTA to the prefrontal cortex. Supports working memory, cognitive flexibility, and attention. D1 receptor tone in this region follows an inverted-U curve — too little or too much degrades performance.

Tuberoinfundibular. Projects from the arcuate nucleus to the median eminence, where dopamine acts as prolactin-inhibiting factor. Antipsychotics that block D2 receptors lift this brake and raise prolactin.

Reward Prediction Error

When an unexpected reward arrives, VTA dopamine neurons fire a phasic burst. When an expected reward is omitted, they pause below baseline. When a reliable cue predicts a forthcoming reward, the burst transfers from the reward itself to the cue. This pattern, identified by Wolfram Schultz and colleagues, implements a temporal-difference learning signal that the brain uses to assign value and update behavior.

Pharmacology

Parkinson's disease is treated with L-DOPA, which bypasses the damaged tyrosine hydroxylase step. Antipsychotics block D2 receptors, easing positive symptoms of schizophrenia but risking parkinsonism and hyperprolactinemia. Stimulants such as methylphenidate inhibit DAT, raising synaptic dopamine to treat ADHD. Peptides like Semax and Bromantane are studied for their capacity to upregulate tyrosine hydroxylase and increase dopamine synthesis without direct receptor binding, while Selank modulates dopamine indirectly through its effects on enkephalin turnover.

Signaling Downstream

The receptor-level effects described here are one instance of the broader mechanisms covered in signal transduction. D1 activation ultimately phosphorylates DARPP-32, which inhibits protein phosphatase 1 and locks in a range of downstream phosphorylation events that shape long-term synaptic plasticity in striatal medium spiny neurons.